News Breaks |
|
|
| November 5, 2012 |
| 07:07 EDT |  | ENDP | Endo Health reports Q3 Branded pharmaceutical sales down 2% to $417M
Net sales of Opana ER decreased 36% for the third quarter on 33 percent lower prescriptions. The decrease in Opana ER net sales is primarily a result of the first quarter supply disruption due to the Novartis plant closure in Lincoln, Neb., and a slower return to growth for Opana ER. |
|
|
News For ENDP From The Last 14 Days Check below for free stories on ENDP the last two weeks. |
|
|
| June 13, 2013 |
| 10:28 EDT | | ENDP | Brahman Capital reports 5.65% passive stake in Endo Health
|
|
| June 6, 2013 |
| 10:01 EDT |  | ENDP | On The Fly: Analyst Downgrade Summary
 Subscribe for More Information |
|
| 10:01 EDT |  | ENDP | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 07:53 EDT | | ENDP | Endo Health upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information |
|
| 07:22 EDT |  | ENDP | Endo Health restructuring slightly ahead of schedule, says Jefferies
Subscribe for More Information |
|
| 06:34 EDT | | ENDP | Endo Health downgraded to Sell from Hold at Cantor
Subscribe for More Information |
|
| June 5, 2013 |
| 17:45 EDT | | ENDP | Endo terminates sales and promotional pact with Ventiv
Subscribe for More Information |
|
| 16:30 EDT |  | ENDP | Endo Health revises FY13 adjusted EPS view to $4.10-$4.40, consensus $4.27
Revises FY13 revenue guidance to $2.65B-$2.8B, consensus $2.8B. The company's 2013 guidance is based on certain assumptions including adjusted gross margin of between 64%-66%; adjusted effective tax rate of between 27.5%-28.5%; adjusted operating expenses to be reduced by approximately $150M when compared with FY12; the company continues to expect a single generic competitor for Lidoderm in September. |
|
| 16:23 EDT | | ENDP | Endo Health to explore strategic alternatives for HealthTronics business
In keeping with its more disciplined capital allocation framework, the company is evaluating strategic alternatives for its HealthTronics business, which provides urological services, products and support systems to various healthcare providers in the U.S. Endo also announced plans to explore alternatives for its branded pharmaceutical early stage discovery platform, which is made up of several drug discovery candidates in multiple therapeutic areas. The company will continue to evaluate the performance of its remaining businesses so that their respective cash flows and returns are consistent with Endo's investment criteria. |
|
| 16:23 EDT | | ENDP | Endo Health, announces strategic alternatives, to reduce workforce by 15%
Subscribe for More Information |
| |
|
|
|
|
